| SEC Form 4 |
|------------|
|------------|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB ADDDOV/AL

| OMB Number: 3235-0287 | | | | | | | | | | |
|--------------------------|-------|--|--|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | | | |
| hours per response | : 0.5 | | | | | | | | | |

| | Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
|--|--|
|--|--|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person [*] Hassanein Waleed H | | | 2. Issuer Name and Ticker or Trading Symbol TransMedics Group, Inc. [TMDX] | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | |
|--|--------------------|------------------|--|---|--|-----------------------|--|--|--|
| | | | [| X | Director | 10% Owner | | | |
| (Last) C/O TRANSM 200 MINUTE | MEDICS GROUP, INC. | | 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023 | - x | Officer (give title below) President & | Other (specify below) | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) ANDOVER | , | | | X | Form filed by One Re | | | | |
| (City) | (State) | (Zip) | — | | Form filed by More th Person | an One Reporting | | | |
| | | Table I - Non-De | rivative Securities Acquired, Disposed of, or Ben | eficially | v Owned | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Disposed Of | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---|-----------------------------|---|------------------------------|---------------|-------------------------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | |
| Common Stock | 03/01/2023 | | S ⁽¹⁾ | | 2,600 | D | \$80.17 ⁽²⁾ | 386,017 | D | |
| Common Stock | 03/01/2023 | | S ⁽¹⁾ | | 4,900 | D | \$81.01 ⁽³⁾ | 381,117 ⁽⁴⁾ | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | (371 | , | | | , | • • | | | | , | | | |
|---|---|--|---|------------------------------|---|---------------|-----|---------------------|--|-------|--|---|--|--|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of Expiration | | Expiration Da | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | e and ınt of rities rlying ative rity (Instr. 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownershi (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$79.47 to \$80.46, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range 3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$80.53 to \$81.51, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 4. Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

By: /s/ Stephen Gordon, Attorney-in-Fact

03/02/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.